Bristol Myers Squibb Presents New Data at ASH 2023 Demonstrating Clinical Benefit Across B-cell Malignancies with Breyanzi as a Second-Line Treatment in High-Risk Follicular Lymphoma and in Relapsed or Refractory Chronic Lymphocytic Leukemia
In TRANSCEND FL, 95.7% of patients with high-risk relapsed or refractory follicular lymphoma (FL) treated with Breyanzi in the second-line setting achieved a complete... Read more.
Mitsubishi Electric and TXOne Networks to Cooperate in Mutual Expansion of OT Security Businesses
TOKYO–(BUSINESS WIRE)–Mitsubishi Electric Corporation and TXOne Networks Inc. announced today that they have signed a long-term cooperation agreement... Read more.
Boosting Business Acumen: Chicago Booth’s Executive Education Program in Finance Workshop for Non-Financial Leaders–Available in Hong Kong and Chicago
CHICAGO–(BUSINESS WIRE)–#ChicagoBoothExecEd–The University of Chicago Booth School of Business introduces The Chicago Booth Approach to Finance... Read more.
New Operation HOPE Research Finds That Financial Literacy Resources, Tools & Coaching Services Are Key Drivers of Optimism Despite Uncertain Economic Times
More than 3,500 HOPE Clients Responded to First-Ever Operation HOPE-Backed Survey, Providing Key Insights into a Broad Cross Section of American Financial Sentiment... Read more.
Long-term ALPHA Phase III trial data showed danicopan as add-on to ULTOMIRIS® or SOLIRIS® sustained clinical improvements in subset of patients with PNH experiencing clinically significant extravascular hemolysis
Data demonstrated effective control of intravascular and extravascular hemolysis through 48 weeks Results showed increase in mean hemoglobin levels were maintained... Read more.
MorphoSys’ Pelabresib Improves All Four Hallmarks of Myelofibrosis in Phase 3 MANIFEST-2 Study
Pelabresib and ruxolitinib combination significantly reduced spleen size, with an SVR35 response rate nearly double that of placebo plus ruxolitinib Showed a strong... Read more.
Latest Data of InnoCare’s Oncology Pipelines Presented at the 65th Annual Meeting of ASH
BEIJING–(BUSINESS WIRE)–InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune... Read more.
New Data for Genentech’s Columvi and Lunsumio Presented at ASH 2023 Support Continued Benefit for People With Lymphoma
– Longer-term data from pivotal studies of fixed-duration Columvi and Lunsumio continue to show durable responses in people with heavily pre-treated lymphomas... Read more.
ADCETRIS® (brentuximab vedotin) Plus Novel Immunotherapy Combination Delivers 100% Progression Free Survival at 12 months in Phase 2 Trial of Patients with Early Stage Classical Hodgkin Lymphoma
– 88% of patients with advanced stage classical Hodgkin Lymphoma in trial remained progression free at 24 months – – Investigational regimen that eliminates... Read more.
VINSSEN Co., Ltd. Successfully Supplies Hydrogen Fuel Cell for Industry Project in Singapore
Working with key industry partners to trial hydrogen as a marine fuel Successful factory inspection and delivery of hydrogen fuel cell for maritime auxiliary power... Read more.